Yayınlanmış 1 Ocak 2020
| Sürüm v1
Dergi makalesi
Açık
Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model
Oluşturanlar
- 1. Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA
- 2. Bezmialem Vakif Univ, Beykoz Inst Life Sci & Biotechnol, Istanbul 34820, Turkey
- 3. Tulane Univ, Dept Trop Med, New Orleans, LA 70112 USA
- 4. Inovio Pharmaceut Inc, Plymouth Meeting, PA 19462 USA
Açıklama
The need for a malaria vaccine is indisputable. A single vaccine for Plasmodium pre-erythrocytic stages targeting the major sporozoite antigen circumsporozoite protein (CSP) has had partial success. Additionally, CD8+ T cells targeting liver-stage (LS) antigens induced by live attenuated sporozoite vaccines were associated with protection in human challenge experiments. To further evaluate protection mediated by LS antigens, we focused on exported pre-erythrocytic proteins (exported protein 1 (EXP1), profilin (PFN), exported protein 2 (EXP2), inhibitor of cysteine proteases (ICP), transmembrane protein 21 (TMP21), and upregulated in infective sporozoites-3 (UIS3)) expressed in all Plasmodium species and designed optimized, synthetic DNA (synDNA) immunogens. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%-88% in non-adjuvanted groups were protected from blood-stage disease following Plasmodium yoelii sporozoite challenge. This study supports the potential of synDNA LS antigens as vaccine components for malaria parasite infection.
Dosyalar
bib-3bb959c7-3123-4db1-9158-2bf0136cfb96.txt
Dosyalar
(325 Bytes)
| Ad | Boyut | Hepisini indir |
|---|---|---|
|
md5:c628bc398cb8f62afed821ffd99525e1
|
325 Bytes | Ön İzleme İndir |